6.61
Precedente Chiudi:
$5.24
Aprire:
$6.625
Volume 24 ore:
3.68M
Relative Volume:
1.40
Capitalizzazione di mercato:
$588.32M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+13.18%
1M Prestazione:
+32.73%
6M Prestazione:
+85.67%
1 anno Prestazione:
+253.48%
Atyr Pharma Inc Stock (ATYR) Company Profile
Nome
Atyr Pharma Inc
Settore
Industria
Telefono
(858) 731-8389
Indirizzo
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Confronta ATYR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ATYR
Atyr Pharma Inc
|
6.61 | 466.38M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-02-18 | Iniziato | Leerink Partners | Outperform |
2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
2024-10-04 | Iniziato | Wells Fargo | Overweight |
2024-09-05 | Iniziato | Jefferies | Buy |
2023-07-05 | Downgrade | Oppenheimer | Outperform → Perform |
2021-10-12 | Iniziato | RBC Capital Mkts | Outperform |
2021-09-21 | Iniziato | Piper Sandler | Overweight |
2021-05-10 | Iniziato | Laidlaw | Buy |
2020-08-17 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-03-04 | Iniziato | ROTH Capital | Buy |
2020-03-02 | Iniziato | Oppenheimer | Outperform |
2018-02-14 | Downgrade | JP Morgan | Neutral → Underweight |
2017-09-07 | Iniziato | Piper Jaffray | Overweight |
2016-12-13 | Downgrade | JP Morgan | Overweight → Neutral |
2015-12-16 | Iniziato | Citigroup | Neutral |
2015-06-01 | Iniziato | Citigroup | Buy |
2015-06-01 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Atyr Pharma Inc Borsa (ATYR) Ultime notizie
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga
aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest
aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada
Is aTyr Pharma Inc. a good long term investmentRecord-breaking gains - Autocar Professional
What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional
aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire
What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com
aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st
aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
RNA Therapeutics and RNA Vaccines Market Industry Report 2025-2035: Investments in RNA Technologies Surge with USD 2.9 Billion Funding - GlobeNewswire Inc.
What makes aTyr Pharma Inc. stock price move sharplyFree Stock Trading Community - beatles.ru
How aTyr Pharma Inc. stock performs during market volatilityTop Growth Low Risk Stocks - Newser
Why aTyr Pharma Inc. stock attracts strong analyst attentionProven Win Setups - Newser
Can ATyr's EFZO-FIT Data Help Patients And Investors Breathe Easier? - RTTNews
Pulmonary Sarcoidosis Market on Track for Major Expansion - openPR.com
Pulmonary Sarcoidosis Market on Track for Major Expansion by 2032, According to DelveInsight | aTyr Pharma, Kinevant Sciences, Novartis, aTyr Pharma, Novartis Pharma, Mallinckrodt - Barchart.com
Favourable Signals For aTyr Pharma: Numerous Insiders Acquired Stock - Yahoo Finance
aTyr Pharma: Insider Buys and Russell 2000 Inclusion Signal a Rare Buying Opportunity - AInvest
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying - MSN
ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell Small Cap Comp Value Index - MarketScreener
ATyr Pharma, Inc.(NasdaqCM: ATYR) added to Russell 3000E Value Index - MarketScreener
Leerink Partners Sticks to Its Buy Rating for aTyr Pharma (ATYR) - The Globe and Mail
aTyr Pharma to join Russell 2000 and 3000 indexes By Investing.com - Investing.com India
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Clinical-Stage Biotech aTyr Pharma Secures Dual Russell Index Addition, Expanding Market Presence - Stock Titan
Is aTyr Pharma, Inc. technically bullish or bearish? - MarketsMojo
Kingswood Wealth Advisors LLC Sells 10,000 Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) - Defense World
aTyr Pharma (ATYR) Sees Price Target Raised Amid Optimism for Ph - GuruFocus
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backing - Yahoo Finance
Bank of America Corp DE Makes New $330,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR) - MarketBeat
Cantor Fitzgerald Comments on Atyr PHARMA FY2026 Earnings - MarketBeat
Atyr Pharma Inc Azioni (ATYR) Dati Finanziari
Non sono disponibili dati finanziari per Atyr Pharma Inc (ATYR). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Atyr Pharma Inc Azioni (ATYR) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
SCHIMMEL PAUL | Director |
Jul 24 '24 |
Buy |
1.93 |
52,300 |
101,038 |
413,023 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):